Bangkok Genomics Innovation PCL (BKK:BKGI) Beneish M-Score: -0.25 (As of Jun. 28, 2026)


BKK:BKGI Bangkok Genomics Innovation PCL BKK:BKGI
45 GF Score
Price ฿2.02
! 12 Warning Signs
View Full Analysis

What is Bangkok Genomics Innovation PCL Beneish M-Score?

Bangkok Genomics Innovation PCL BKK:BKGI -2.88% 45 Beneish M-Score is -0.25 as of Jun. 28, 2026. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks worse than 93.3% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.25 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Beneish M-Score or its related term are showing as below:

BKK:BKGI' s Beneish M-Score Range Over the Past 10 Years
Min: -2.29   Med: -0.73   Max: -0.25
Current: -0.25

During the past 7 years, the highest Beneish M-Score of Bangkok Genomics Innovation PCL was -0.25. The lowest was -2.29. And the median was -0.73.


Bangkok Genomics Innovation PCL Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bangkok Genomics Innovation PCL's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Genomics Innovation PCL Beneish M-Score Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 -2.29 -0.73 -0.25

Bangkok Genomics Innovation PCL Quarterly Data
Dec19 Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -1.24 -1.61 -1.49 -0.25

BKK:BKGI vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Genomics Innovation PCL Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Beneish M-Score falls into.


BKK:BKGI
45GF Score
Bangkok Genomics Innovation PCL BKK:BKGI
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bangkok Genomics Innovation PCL Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bangkok Genomics Innovation PCL for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.8436+0.528 * 1.0118+0.404 * 2.8246+0.892 * 1.1242+0.115 * 0.8387
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0482+4.679 * 0.196606-0.327 * 1.8965
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was ฿166.4 Mil.
Revenue was 142.264 + 88.917 + 69.795 + 78.535 = ฿379.5 Mil.
Gross Profit was 59.433 + 33.716 + 29.008 + 33.469 = ฿155.6 Mil.
Total Current Assets was ฿580.4 Mil.
Total Assets was ฿701.9 Mil.
Property, Plant and Equipment(Net PPE) was ฿76.7 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿21.5 Mil.
Selling, General, & Admin. Expense(SGA) was ฿111.4 Mil.
Total Current Liabilities was ฿126.8 Mil.
Long-Term Debt & Capital Lease Obligation was ฿16.6 Mil.
Net Income was 26.007 + 6.926 + 4.295 + 8.122 = ฿45.4 Mil.
Non Operating Income was -0.005 + -0.093 + -0.119 + -0.107 = ฿-0.3 Mil.
Cash Flow from Operations was -102.461 + 1.699 + 11.813 + -3.366 = ฿-92.3 Mil.
Total Receivables was ฿80.3 Mil.
Revenue was 95.77 + 87.719 + 85.783 + 68.321 = ฿337.6 Mil.
Gross Profit was 38.802 + 35.86 + 34.422 + 30.993 = ฿140.1 Mil.
Total Current Assets was ฿514.9 Mil.
Total Assets was ฿607.6 Mil.
Property, Plant and Equipment(Net PPE) was ฿79.0 Mil.
Depreciation, Depletion and Amortization(DDA) was ฿17.8 Mil.
Selling, General, & Admin. Expense(SGA) was ฿94.5 Mil.
Total Current Liabilities was ฿45.7 Mil.
Long-Term Debt & Capital Lease Obligation was ฿19.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(166.425 / 379.511) / (80.299 / 337.593)
=0.438525 / 0.237857
=1.8436

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(140.077 / 337.593) / (155.626 / 379.511)
=0.414929 / 0.41007
=1.0118

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (580.355 + 76.735) / 701.856) / (1 - (514.924 + 78.951) / 607.595)
=0.063782 / 0.022581
=2.8246

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=379.511 / 337.593
=1.1242

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(17.788 / (17.788 + 78.951)) / (21.546 / (21.546 + 76.735))
=0.183876 / 0.219229
=0.8387

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(111.357 / 379.511) / (94.501 / 337.593)
=0.293422 / 0.279926
=1.0482

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((16.604 + 126.824) / 701.856) / ((19.791 + 45.679) / 607.595)
=0.204355 / 0.107753
=1.8965

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(45.35 - -0.324 - -92.315) / 701.856
=0.196606

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bangkok Genomics Innovation PCL has a M-score of -0.25 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.25 mean?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Beneish M-Score of -0.25 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bangkok Genomics Innovation PCL and its competitors. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #181 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 93.3%.
Is Bangkok Genomics Innovation PCL's Beneish M-Score too high?
Bangkok Genomics Innovation PCL's current Beneish M-Score is -0.25. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #181 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #181 out of 194 companies for Beneish M-Score. This places Bangkok Genomics Innovation PCL in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Beneish M-Score is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Beneish M-Score of -0.25. The current Beneish M-Score is -0.25. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Beneish M-Score is -0.25 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bangkok Genomics Innovation PCL Business Description

Address 3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score

Get the complete analysis for BKK:BKGI

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.02
Price